Skip to content

Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Combined Screening for Cervical Cancer

Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Combined Screening for Cervical Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300079044
Enrollment
Unknown
Registered
2023-12-25
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Outpatients with cervical cancer screening:NO

Sponsors

West China Second Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Outpatient screening patients for cervical cancer disease; 2 Non-pregnant and non-lactating women with a history of sex; 3 No immune system disease; 4 No history of cervical lesions and no history of cervical surgery; 5 Patients who agree to join the group.

Exclusion criteria

Exclusion criteria: 1 Speces using other storage liquids; 2 Patients with HPV unrelated adenocarcinoma or other tumors confirmed to be accompanied by vaginal cancer and vulvar squamous carcinoma; 3 Patients who cannot observe or reach the destination on the way as required; Patients who have had sex within 43 days or have had vaginal medication or treatment.

Design outcomes

Primary

MeasureTime frame
HPV E6/E7 mRNA;HPV DNA type;sensitivity, specificity, positive predictive value, negative predictive value;

Secondary

MeasureTime frame
Cytology;

Countries

China

Contacts

Public ContactLin Li

West China Second Hospital, Sichuan University

lilin0119@scu.edu.cn+86 135 4799 4644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026